[HTML][HTML] Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE
Lutathera® is the first EMA-and FDA-approved radiopharmaceutical for radioligand therapy
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …
The Future Direction of Women in Nuclear Medicine and Nuclear Medicine in Women's Health
L Evangelista, P Guglielmo, A Pietrzak… - Seminars in Nuclear …, 2024 - Elsevier
This work discusses the role of Nuclear Medicine for women's health, the role of women in
the development of this emerging field and the various issues which arise from both. It …
the development of this emerging field and the various issues which arise from both. It …
[HTML][HTML] Sternum Metastases: From Case-Identifying Strategy to Multidisciplinary Management
M Carsote, D Terzea, F Vasilescu, AP Cucu, A Ciuche… - Diagnostics, 2023 - mdpi.com
We aimed to overview the most recent data on sternal metastases from a multidisciplinary
approach (diagnosis strategies, outcome, and histological reports). This narrative review …
approach (diagnosis strategies, outcome, and histological reports). This narrative review …
[HTML][HTML] Case Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re-differentiation strategy?
A 61-year-old woman with a history of metastatic follicular thyroid carcinoma became
radioiodine-refractory following two doses of radioiodine (RAI) therapy (cumulative= 230 …
radioiodine-refractory following two doses of radioiodine (RAI) therapy (cumulative= 230 …